அட்டை சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share:
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) InCarda Therapeutics, Inc. ( InCarda ), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today announced dosing of the first U.S. patient in the company s multinational INSTANT Phase 2 clinical trial of InRhythm
™ (flecainide for inhalation) in patients with recent-onset paroxysmal atrial fibrillation (PAF). The trial is currently being conducted at centers in the U.S. and Europe to evaluate the optimal dose (120 mg) of InRhythm that was selected based on the positive results from the open-label, dose-ranging stage of the INSTANT study.
The results from the dose-ranging stage of the trial were recently presented at the American Heart Association s (AHA) Scientific Sessions 2020. InCarda Therapeutics in collaboration with clinical investigators reported that oral inhaled flecainide can safely and rapidly convert recent-onset PAF to normal si ....

United States , Coll Cardiol , Marky Lee , Luiz Belardinelli , Incarda Therapeutics Inc , American Heart Association , Memorialcare Long Beach Medical Center , Long Beach Medical Center , Incarda Therapeutics , Scientific Sessions , Memorialcare Long Beach Medical , Incarda Therapeutics , Care Long Beach Medical Center , Atrial Fibrillation , ஒன்றுபட்டது மாநிலங்களில் , மார்க்கி லீ , அமெரிக்கன் இதயம் சங்கம் , நீண்டது கடற்கரை மருத்துவ மையம் , அட்டை சிகிச்சை , அறிவியல் அமர்வுகள் , பராமரிப்பு நீண்டது கடற்கரை மருத்துவ மையம் , ஏட்ரியல் குறு நடுக்கம் ,